The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The appointment is effective from May 01, 2023 for five years
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Subscribe To Our Newsletter & Stay Updated
